Trending News Today: FDA Panel Votes Unanimous Support of Rituxan Biosimilar

Celltrion Pharm Inc’s biosimilar of Roche Holding AG’s cancer drug Rituxan received unanimous support from an advisory panel to the FDA, Reuters reported. According to the article, the vote comes after FDA officials found that the biosimilar, CT-P10, was highly similar to Rituxan. In February, the FDA denied approval to the drug citing issues related to certain manufacturing process at Celltrion’s facility, the article reported.
 
A new study suggests that atrial fibrillation may be tied to an increased risk of developing dementia, but treatment with blood thinners appear to reduce that risk, Reuters reported. According to the article, the study authors followed 2685 volunteers who did not have dementia at the outset, although 9% had atrial fibrillation. The authors determined that atrial fibrillation raised the overall risk of dementia by 40% and the risk of vascular and mixed dementias by nearly 90%, but individuals treated with anti-clotting drugs were 60% less likely to develop dementia, the article reported.
 
Health officials in several states, including Illinois, Minnesota, and Colorado, are reporting spikes in cases of a rare nervous system disorder called acute flaccid myelitis (AFM), the Associated Press reported. According to the article, AFM attacks the nervous system and can lead to arm or leg weakness and loss of muscle reflexes. The CDC has indicated there may be some increases in cases and received information on a total of 362 confirmed cases nationwide between August 2014 and August 2018, the article reported.



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of HER2-overexpressing breast cancer. 
Top news of the day across the health care landscape.
Top news of the day across the health care landscape.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$